Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Aromasin
Sponsor: Pfizer